Base de dados : MEDLINE
Pesquisa : G12.450.400 [Categoria DeCS]
Referências encontradas : 500 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 50 ir para página                         

  1 / 500 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449971
[Au] Autor:Tsaban G; Ben-Shimol S
[Ad] Endereço:Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
[Ti] Título:Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature.
[So] Source:Vaccine;35(22):2882-2891, 2017 05 19.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pneumococcal diseases are major causes of morbidity among adults, especially those over 50years of age. While pneumococcal conjugated vaccines (PCV's) impact on pneumococcal disease rates among children is well established, the extent of its impact on adult pneumococcal related illness remains unclear. The aim of this systematic literature review was to describe the impact of PCV introduction to childhood national immunization programs worldwide on PCV-naive adult population. METHODS: A systematic literature search was performed using the PubMed database. The search was limited to articles written in English and published between January 2000 and February 2016. Studies evaluating pneumococcal disease rates in individuals over 5years of age were included. Independent extraction of articles was performed by the two authors. Search terms included: Pneumococcal conjugated vaccine, herd, indirect, adults, and pneumonia. RESULTS: Forty-nine articles meeting the selection criteria were identified, 39 regarding invasive pneumococcal disease (IPD, one on meningitis only), 8 regarding pneumonia, and 2 on both IPD and pneumonia. The majority of reports were from the US, UK and Canada. Considerable variability in the data sources, quality and completeness was observed. While most studies reported either statistically significant reduction or insignificant changes in IPD and pneumonia disease rates in adults following PCV nationwide implementation, few studies reported statistically significant increase in pneumococcal disease rates, these were mainly from countries with low PCV coverage rates and/or inadequate surveillance. CONCLUSION: Invasive pneumococcal diseases and pneumonia rates among the adult population decreased in most countries following PCV introduction into the NIP. This indirect effect on older population seems to be dependent on PCV coverage rates and time from PCV nationwide implementation. Adults >65years old seem to benefit the most from PCV introduction.
[Mh] Termos MeSH primário: Imunidade Coletiva
Programas de Imunização
Vacinas Pneumocócicas/imunologia
Pneumonia Pneumocócica/prevenção & controle
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Canadá/epidemiologia
Criança
Pré-Escolar
Feminino
Seres Humanos
Masculino
Meia-Idade
Infecções Pneumocócicas/epidemiologia
Infecções Pneumocócicas/imunologia
Infecções Pneumocócicas/prevenção & controle
Vacinas Pneumocócicas/administração & dosagem
Pneumonia Pneumocócica/epidemiologia
Pneumonia Pneumocócica/microbiologia
Streptococcus pneumoniae/imunologia
Vacinação
Vacinas Conjugadas/administração & dosagem
Vacinas Conjugadas/imunologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Pneumococcal Vaccines); 0 (Vaccines, Conjugate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  2 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29253379
[Au] Autor:Brisson M; Bénard É; Drolet M; Bogaards JA; Baussano I; Vänskä S; Jit M; Boily MC; Smith MA; Berkhof J; Canfell K; Chesson HW; Burger EA; Choi YH; De Blasio BF; De Vlas SJ; Guzzetta G; Hontelez JAC; Horn J; Jepsen MR; Kim JJ; Lazzarato F; Matthijsse SM; Mikolajczyk R; Pavelyev A; Pillsbury M; Shafer LA; Tully SP; Turner HC; Usher C; Walsh C
[Ad] Endereço:Centre de recherche du CHU de Québec-Université Laval, Quebec City, QC, Canada; Département de médecine sociale et préventive, Université Laval, Quebec City, QC, Canada; Department of Infectious Disease Epidemiology, Imperial College, London, UK. Electronic address: marc.brisson@crchudequebec.ulaval
[Ti] Título:Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
[So] Source:Lancet Public Health;1(1):e8-e17, 2016 Nov.
[Is] ISSN:2468-2667
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Modelling studies have been widely used to inform human papillomavirus (HPV) vaccination policy decisions; however, many models exist and it is not known whether they produce consistent predictions of population-level effectiveness and herd effects. We did a systematic review and meta-analysis of model predictions of the long-term population-level effectiveness of vaccination against HPV 16, 18, 6, and 11 infection in women and men, to examine the variability in predicted herd effects, incremental benefit of vaccinating boys, and potential for HPV-vaccine-type elimination. METHODS: We searched MEDLINE and Embase for transmission-dynamic modelling studies published between Jan 1, 2009, and April 28, 2015, that predicted the population-level impact of vaccination on HPV 6, 11, 16, and 18 infections in high-income countries. We contacted authors to determine whether they were willing to produce new predictions for standardised scenarios. Strategies investigated were girls-only vaccination and girls and boys vaccination at age 12 years. Base-case vaccine characteristics were 100% efficacy and lifetime protection. We did sensitivity analyses by varying vaccination coverage, vaccine efficacy, and duration of protection. For all scenarios we pooled model predictions of relative reductions in HPV prevalence (RR ) over time after vaccination and summarised results using the median and 10th and 90th percentiles (80% uncertainty intervals [UI]). FINDINGS: 16 of 19 eligible models from ten high-income countries provided predictions. Under base-case assumptions, 40% vaccination coverage and girls-only vaccination, the RR of HPV 16 among women and men was 0·53 (80% UI 0·46-0·68) and 0·36 (0·28-0·61), respectively, after 70 years. With 80% girls-only vaccination coverage, the RR of HPV 16 among women and men was 0·93 (0·90-1·00) and 0·83 (0·75-1·00), respectively. Vaccinating boys in addition to girls increased the RR of HPV 16 among women and men by 0·18 (0·13-0·32) and 0·35 (0·27-0·39) for 40% coverage, and 0·07 (0·00-0·10) and 0·16 (0·01-0·25) for 80% coverage, respectively. The RR were greater for HPV 6, 11, and 18 than for HPV 16 for all scenarios investigated. Finally at 80% coverage, most models predicted that girls and boys vaccination would eliminate HPV 6, 11, 16, and 18, with a median RR of 1·00 for women and men for all four HPV types. Variability in pooled findings was low, but increased with lower vaccination coverage and shorter vaccine protection (from lifetime to 20 years). INTERPRETATION: Although HPV models differ in structure, data used for calibration, and settings, our population-level predictions were generally concordant and suggest that strong herd effects are expected from vaccinating girls only, even with coverage as low as 20%. Elimination of HPV 16, 18, 6, and 11 is possible if 80% coverage in girls and boys is reached and if high vaccine efficacy is maintained over time. FUNDING: Canadian Institutes of Health Research.
[Mh] Termos MeSH primário: Imunidade Coletiva/imunologia
Infecções por Papillomavirus/imunologia
Vacinas contra Papillomavirus/uso terapêutico
[Mh] Termos MeSH secundário: Erradicação de Doenças
Feminino
Seres Humanos
Masculino
Modelos Estatísticos
Infecções por Papillomavirus/epidemiologia
Infecções por Papillomavirus/prevenção & controle
Infecções por Papillomavirus/transmissão
Vacinas contra Papillomavirus/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE


  3 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29320811
[Au] Autor:Skinner E
[Ad] Endereço:National Conference of State Legislatures, Denver, Colorado.
[Ti] Título:Vaccination Policies: Requirements and Exemptions for Entering School.
[So] Source:NCSL Legisbrief;25(48):1-2, 2017 Dec.
[Is] ISSN:1068-2716
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:(1) According to the World Health Organization, immunization prevents between 2 million to 3 million deaths every year across the world. (2) When immunization rates are high, herd immunity develops and limits the spread of the disease, which helps protect those who cannot be vaccinated. (3) Vaccination rates for measles, mumps and rubella vary across the United States, ranging from 85.6 percent in Washington, D.C., to 99.4 percent in Mississippi.
[Mh] Termos MeSH primário: Política de Saúde/legislação & jurisprudência
Imunização/estatística & dados numéricos
Instituições Acadêmicas/legislação & jurisprudência
Vacinação/legislação & jurisprudência
Vacinas/uso terapêutico
[Mh] Termos MeSH secundário: Pré-Escolar
Governo Federal
Seres Humanos
Imunidade Coletiva
Esquemas de Imunização
Programas Obrigatórios/legislação & jurisprudência
Vacina contra Sarampo-Caxumba-Rubéola/uso terapêutico
Governo Estadual
Estados Unidos
Vacinação/estatística & dados numéricos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Measles-Mumps-Rubella Vaccine); 0 (Vaccines)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180122
[Lr] Data última revisão:
180122
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE


  4 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457742
[Au] Autor:Linares-Pérez N; Toledo-Romaní ME; Santana-Mederos D; García-Fariñas A; García-Rivera D; Valdés-Balbín Y; Vérez-Bencomo V
[Ad] Endereço:Finlay Vaccine Institute, Havana, Cuba. Electronic address: nlinares@finlay.edu.cu.
[Ti] Título:From individual to herd protection with pneumococcal vaccines: the contribution of the Cuban pneumococcal conjugate vaccine implementation strategy.
[So] Source:Int J Infect Dis;60:98-102, 2017 Jul.
[Is] ISSN:1878-3511
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:A new pneumococcal conjugate vaccine is currently undergoing advanced clinical evaluation prior to its planned introduction in Cuba. The implementation of the pneumococcal vaccination strategy has been designed with consideration of the need to maximize both its direct and indirect effects. A novel approach is suggested, which addresses preschool children as the first-line target group to generate herd immunity in infants and to have an impact on transmission at the community level. The clinical evaluation pipeline is described herein, including evaluations of effectiveness, cost-effectiveness, and impact. The scientific contribution of the Cuban strategy could support a paradigm shift from individual protection to a population effect based on a rigorous body of scientific evidence.
[Mh] Termos MeSH primário: Imunidade Coletiva
Infecções Pneumocócicas/prevenção & controle
Vacinas Pneumocócicas
Vacinação/normas
[Mh] Termos MeSH secundário: Pré-Escolar
Análise Custo-Benefício
Cuba
Seres Humanos
Lactente
Nasofaringe/microbiologia
Infecções Pneumocócicas/epidemiologia
Vacinas Pneumocócicas/economia
Vacinas Pneumocócicas/imunologia
Vacinas Pneumocócicas/normas
Streptococcus pneumoniae/imunologia
Streptococcus pneumoniae/isolamento & purificação
Vacinação/economia
Vacinas Conjugadas/economia
Vacinas Conjugadas/imunologia
Vacinas Conjugadas/normas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pneumococcal Vaccines); 0 (Vaccines, Conjugate)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171222
[Lr] Data última revisão:
171222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  5 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28450197
[Au] Autor:Rodgers GL; Klugman KP
[Ad] Endereço:Bill and Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109, USA.
[Ti] Título:A new paradigm in pneumococcal conjugate vaccination: moving from individual to herd protection.
[So] Source:Int J Infect Dis;60:96-97, 2017 07.
[Is] ISSN:1878-3511
[Cp] País de publicação:Canada
[La] Idioma:eng
[Mh] Termos MeSH primário: Imunidade Coletiva
Vacinação
[Mh] Termos MeSH secundário: Seres Humanos
Infecções Pneumocócicas/prevenção & controle
Vacinas Pneumocócicas
Vacinas Conjugadas
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Nm] Nome de substância:
0 (Pneumococcal Vaccines); 0 (Vaccines, Conjugate)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  6 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28931217
[Au] Autor:Oliver SE; Unger ER; Lewis R; McDaniel D; Gargano JW; Steinau M; Markowitz LE
[Ad] Endereço:Division of Viral Diseases, National Center for Immunization and Respiratory Diseases.
[Ti] Título:Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.
[So] Source:J Infect Dis;216(5):594-603, 2017 Sep 01.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Human papillomavirus (HPV) vaccine was recommended in 2006 for routine vaccination of US females aged 11-12 years. Most vaccine used through 2014 was quadrivalent vaccine (4vHPV), which prevents HPV-6, -11, -16, and -18 infection. To evaluate vaccine impact, we measured HPV prevalence in the National Health and Nutrition Examination Survey (NHANES). Methods: We analyzed HPV DNA types detected in self-collected cervicovaginal specimens and demographic, sexual behavior, and self-reported vaccination data from females 14-34 years old. We estimated HPV prevalence in the prevaccine (2003-2006) and vaccine eras (2007-2010 and 2011-2014). Results: Among 14- to 19-year-olds, 4vHPV-type prevalence decreased from 11.5% (95% confidence interval [CI], 9.1%-14.4%) in 2003-2006 to 3.3% (95% CI, 1.9%-5.8%) in 2011-2014, when ≥1-dose coverage was 55%. Among 20- to 24-year-olds, prevalence decreased from 18.5% (95% CI, 14.9%-22.8%) in 2003-2006 to 7.2% (95% CI, 4.7%-11.1%) in 2011-2014, when ≥1-dose coverage was 43%. Compared to 2003-2006, 4vHPV prevalence in sexually active 14- to 24-year-olds in 2011-2014 decreased 89% among those vaccinated and 34% among those unvaccinated. Vaccine effectiveness was 83%. Conclusions: Within 8 years of vaccine introduction, 4vHPV-type prevalence decreased 71% among 14- to 19-year-olds and 61% among 20- to 24-year-olds. Estimated vaccine effectiveness was high. The decrease in 4vHPV-type prevalence among unvaccinated females suggests herd protection.
[Mh] Termos MeSH primário: Papillomaviridae/isolamento & purificação
Infecções por Papillomavirus/epidemiologia
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Adulto
Estudos Transversais
DNA Viral/isolamento & purificação
Feminino
Seres Humanos
Imunidade Coletiva
Meia-Idade
Inquéritos Nutricionais
Prevalência
Comportamento Sexual
Manejo de Espécimes
Estados Unidos/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Viral); 0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170922
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix244


  7 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28885413
[Au] Autor:Berenson AB; Hirth JM; Chang M
[Ad] Endereço:Center for Interdisciplinary Research in Women's Health and the Department of Obstetrics & Gynecology, the University of Texas Medical Branch, Galveston, Texas.
[Ti] Título:Change in Human Papillomavirus Prevalence Among U.S. Women Aged 18-59 Years, 2009-2014.
[So] Source:Obstet Gynecol;130(4):693-701, 2017 Oct.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To examine changes in prevalence of vaginal human papillomavirus (HPV) between 2009-2010 and 2013-2014 among both vaccinated and unvaccinated U.S. women. METHODS: We evaluated HPV prevalence among women 18-59 years old using cross-sectional survey data from three different cycles of the National Health and Nutrition Examination Survey. Data were stratified into four age groups (18-26, 27-34, 35-44, and 45-49 years) to examine trends over time among women of different ages in the postvaccine era. Multivariable analyses, which controlled for descriptive variables, were used to examine the prevalence of quadrivalent vaccine-type HPV by vaccination status. RESULTS: We observed a significant decrease in the prevalence of vaccine-type HPV among women 18-59 years of age from 2009-2010 to 2013-2014. This decline was only significant in those 18-26 years old when the sample was stratified into the four age groups. Among vaccinated 18-26 year olds, HPV prevalence remained low from 2009-2010 (3.9%) to 2013-2014 (2.0%; prevalence ratio 0.51, 95% CI 0.18-1.46). Unvaccinated women 18-26 years old also demonstrated a significant decrease over time from 19.5% in 2009-2010 to 9.7% in 2013-2014 (prevalence ratio 0.44, 95% CI 0.22-0.91). Prevalence did not significantly change among unvaccinated women 26 years old or older. CONCLUSIONS: The decline in HPV infections among unvaccinated 18- to 26-year-old women suggests that young women in the United States are beginning to benefit from herd immunity resulting from the introduction of the HPV vaccine.
[Mh] Termos MeSH primário: Papillomaviridae
Infecções por Papillomavirus/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Estudos Transversais
Feminino
Seres Humanos
Imunidade Coletiva
Meia-Idade
Inquéritos Nutricionais
Infecções por Papillomavirus/prevenção & controle
Infecções por Papillomavirus/virologia
Vacinas contra Papillomavirus/uso terapêutico
Prevalência
Estados Unidos/epidemiologia
Vacinação/estatística & dados numéricos
Vagina/virologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170909
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002193


  8 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28859431
[Au] Autor:Baussano I; Lazzarato F; Ronco G; Lehtinen M; Dillner J; Franceschi S
[Ad] Endereço:International Agency for Research on Cancer, Lyon, France.
[Ti] Título:Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.
[So] Source:J Infect Dis;216(3):336-344, 2017 Aug 01.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Human papillomavirus (HPV) vaccination is still not reaching many high-risk populations. HPV16/18 vaccines offer cross-protection against other types, for example, HPV45. Both direct vaccine efficacy and indirect herd protection contribute to vaccination effectiveness. Methods: We used a dynamic transmission model, calibrated to cervical screening data from Italy, to estimate vaccination effectiveness against HPV16 and HPV45 infection, assuming for HPV45 either 95% or lower cross-protection. Results: Basic reproductive number was smaller (2.1 vs 4.0) and hence vaccine effectiveness and herd protection stronger for HPV45 than for HPV16. The largest difference in the reduction of infection prevalence in women <35 years old was found at 70% coverage in girls-only vaccination programs (99% vs 83% for total protection for HPV45 and HPV16, respectively, mainly owing to stronger herd protection, ie, 37% vs 16%). In gender-neutral vaccination, the largest difference was at 40% coverage (herd protection, 54% vs 28% for HPV16 and HPV45, respectively). With ≥80% coverage, even 50% cross-protection would reduce HPV45 by ≥94%. Conclusions: The characteristics of individual high-risk HPV types strongly influence herd protection and determine the level of coverage and cross-protection required to reduce or eliminate the infection through HPV vaccination. HPV16 infection and related cancers are the most difficult to eliminate.
[Mh] Termos MeSH primário: Papillomavirus Humano 16
Papillomavirus Humano 18
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus/administração & dosagem
Neoplasias do Colo do Útero/prevenção & controle
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Criança
Proteção Cruzada/imunologia
Feminino
Seres Humanos
Imunidade Coletiva/imunologia
Programas de Imunização
Itália
Masculino
Meia-Idade
Modelos Teóricos
Neoplasias do Colo do Útero/virologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170902
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix299


  9 / 500 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28855247
[Au] Autor:Brooke CB
[Ad] Endereço:Department of Microbiology and Carl R. Woese Institute for Genomic Biology, University of Illinois, Urbana, Illinois, USA cbrooke@illinois.edu.
[Ti] Título:Population Diversity and Collective Interactions during Influenza Virus Infection.
[So] Source:J Virol;91(22), 2017 Nov 15.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Influenza A virus (IAV) continues to pose an enormous and unpredictable global public health threat, largely due to the continual evolution of escape from preexisting immunity and the potential for zoonotic emergence. Understanding how the unique genetic makeup and structure of IAV populations influences their transmission and evolution is essential for developing more-effective vaccines, therapeutics, and surveillance capabilities. Owing to their mutation-prone replicase and unique genome organization, IAV populations exhibit enormous amounts of diversity both in terms of sequence and functional gene content. Here, I review what is currently known about the genetic and genomic diversity present within IAV populations and how this diversity may shape the replicative and evolutionary dynamics of these viruses.
[Mh] Termos MeSH primário: Variação Genética
Imunidade Coletiva
Vírus da Influenza A
Vacinas contra Influenza
Influenza Humana
[Mh] Termos MeSH secundário: Seres Humanos
Vírus da Influenza A/genética
Vírus da Influenza A/imunologia
Vacinas contra Influenza/genética
Vacinas contra Influenza/imunologia
Vacinas contra Influenza/uso terapêutico
Influenza Humana/genética
Influenza Humana/imunologia
Influenza Humana/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Influenza Vaccines)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE


  10 / 500 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28806926
[Au] Autor:Thöne K; Horn J; Mikolajczyk R
[Ad] Endereço:Leibniz-Institute for Prevention Research and Epidemiology - BIPS, Achterstr. 30, 28359, Bremen, Germany.
[Ti] Título:Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data.
[So] Source:BMC Infect Dis;17(1):564, 2017 Aug 14.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Shortly after the human papillomavirus (HPV) vaccine recommendation and hence the reimbursement of vaccination costs for the respective age groups in Germany in 2007, changes in the incidence of anogenital warts (AGWs) were observed, but it was not clear at what level the incidence would stabilize and to what extent herd immunity would be present. Given the relatively low HPV vaccination coverage in Germany, we aimed to assess potential vaccination herd immunity effects in the German setting. METHODS: A retrospective open cohort study with data from more than nine million statutory health insurance members from 2005 to 2010 was conducted. AGW cases were identified using ICD-10-codes. The incidence of AGWs was estimated by age, sex, and calendar quarter. Age and sex specific incidence rate ratios were estimated comparing the years 2009-2010 (post-vaccination period) with 2005-2007 (pre-vaccination period). RESULTS: Incidence rate ratio of AGWs for the post-vaccination period compared to the pre-vaccination period showed a u-shaped decrease among the 14- to 24-year-old females and males which corresponds well with the reported HPV vaccination uptake in 2008. A maximum reduction of up to 60% was observed for the 16- to 20-year-old females and slightly less pronounced (up to 50%) for the 16- and 18-year-old males. Age groups outside of the range 14-24 years demonstrated no decrease. The decrease of incidence occurred in both sexes early after the vaccine recommendation and stabilized at lower levels in 2009-2010. CONCLUSIONS: A relative reduction of up to 50% among males of approximately similar age groups as that of females receiving the HPV vaccination suggests herd protection resulting from assortative mixing by age. The early decrease among males can be reduced over time due to partner change.
[Mh] Termos MeSH primário: Condiloma Acuminado/epidemiologia
Imunidade Coletiva
Vacinas contra Papillomavirus/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Feminino
Alemanha/epidemiologia
Seres Humanos
Incidência
Seguro Saúde/estatística & dados numéricos
Análise de Séries Temporais Interrompida
Masculino
Infecções por Papillomavirus/epidemiologia
Estudos Retrospectivos
Vacinação/estatística & dados numéricos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170816
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2663-7



página 1 de 50 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde